Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: Efficacy, safety and non-compartmental pharmacokinetics

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 1, 1999, Pages 95-103

  Groll, Andreas H ^c   Gonzalez, Corina E ^c   Giri, Neelam ^c   Kligys, Krystina ^c   Love, William ^c   Peter, Joanne ^c   Feuerstein, Erwin ^c   Bacher, John ^c   Piscitelli, Stephen C ^a   Walsh, Thomas J ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CREATININE; NITROGEN; NYSTATIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LUNG ASPERGILLOSIS; LUNG WEIGHT; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; RABBIT; SURVIVAL RATE; UREA NITROGEN BLOOD LEVEL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; ASPERGILLOSIS; BLOOD UREA NITROGEN; CREATININE; DRUG CARRIERS; FEMALE; HALF-LIFE; LIPOSOMES; LUNG; LUNG DISEASES, FUNGAL; NEUTROPENIA; NYSTATIN; ORGAN SIZE; RABBITS; SURVIVAL RATE;

EID: 0032949096     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.1.95     Document Type: Article

References (32)

1. Anaissie, E. (1992). Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clinical Infectious Diseases 14, Suppl. 1, 43-53.
2. Pannuti, C. S., Gingrich, R. D., Pfaller, M. A. & Wenzel, R. P. (1991). Nosocomial pneumonia in adult patients undergoing bone marrow transplantation : a 9-year study. Journal of Clinical Oncology 9, 77-84.
3. Weinberger, M., Elattar, I., Marshall, D., Steinberg, S. M., Redner, R. L., Young, N. S. et al. (1992). Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as major cause of death. Medicine 71, 24-43.
4. Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Nuebling, G. & Huebner, K. (1996). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. Journal of Infection 33, 23-32.
5. Denning, D. W. (1996). Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases 23, 608-15.
6. Hiemenz, J. W. & Walsh, T. J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clinical Infectious Diseases 22, Suppl. 2, S133-44.
7. Hazen, E. L. & Brown, R. (1950). Two antifungal agents produced by a soil actinomycete. Science 112, 423.
8. Hamilton-Miller, J. M. T. (1973). Chemistry and biology of the polyene macrolide antibiotics. Bacteriological Reviews 37, 166-96.
9. Mehta, R. T., Hopfer, R. L., Gunner, L. A., Juliano, R. L. & Lopez-Berestein, G. (1987). Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrobial Agents and Chemotherapy 31, 1897-900.
10. Mehta, R. T., Hopfer, R. L., McQueen, T., Juliano, R. L. & Lopez-Berestein, G. (1987). Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrobial Agents and Chemotherapy 31, 1901-3.
11. Wallace, T. L., Paetznick, V., Cossum, P. A., Lopez-Berestein, G., Rex, J. H. & Anaissie, E. (1997). Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrobial Agents and Chemotherapy 41, 2238-43.
12. Boutati, E., Maltezou, H. C., Lopez-Berestein, G., Vartivarian, S. E. & Anaissie, E. (1995). Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with haematological malignancies. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract LM 22, p. 330. American Society for Microbiology, Washington, DC.
13. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. (1996). Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
14. Walsh, T. J., Bacher, P. & Pizzo, P. A. (1988). Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Laboratory Animal Science 38, 467-71.
15. Vaughan, V. C. & Litt, I. F. (1992). Growth and Development. In Textbook of Pediatrics, 14th edn (Behrman, R. E., Kliegman, R. M., Nelson, W. E. & Vaughan, V. C., Eds), p. 40. W. B. Saunders, Philadelphia, PA.
16. Espinel-Ingroff, A., Dawson, K., Pfaller, M., Anaissie, E., Breslin, E., Dixon, D. et al. (1995). Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrobial Agents and Chemotherapy 39, 314-9.
17. Walsh, T. J., McEntee, C. & Dixon, D. M. (1987). Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. Journal of Clinical Microbiology 25, 931-2.
18. Walsh, T. J., Garrett, K., Feuerstein, E., Girton, M., Allende, M., Bacher, J. et al. (1995). Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrobial Agents and Chemotherapy 39, 1065-9.
19. Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P., Yacobi, A. et al. (1991). Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. European Journal of Drug Metabolism and Pharmacokinetics 16, 249-55.
20. Gibaldi, M. & Perrier, D. (1982). Pharmacokinetics, 2nd edn. Marcel Dekker, Inc., New York.
21. Schneider, M. (1985). Liposomes as drug carriers: 10 years of research. In Drug Targeting (Buri, P. & Gumma, A., Eds), pp. 119-34. Elsevier Science Publishers, New York.
22. Rios, A., Rosenblum, M., Crofoot, G., Lenk, R. P., Hayman, A. & Lopez-Berestein, G. (1993). Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 168, 253-4.
23. Cossum, P. A., Wyse, J., Simmons, Y., Wallace, T. L. & Rios, A. (1996). Pharmacokinetics of Nyotran (liposomal nystatin) in human patients. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract A88, p. 17. American Society for Micro biology, Washington, DC.
24. Jessup, C. J., Wallace, T. L. & Ghannoum, M. A. (1997). Evaluation of antifungal activity of Nyotran against various pathogenic fungi. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract F88, p. 161. American Society for Microbiology, Washington, DC.
25. Johnson, E. M., Ojwang, J. O., Szekely, A., Wallace, T. L. & Warnock, D. W. (1998). Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrobial Agents and Chemotherapy 42, 1412-6.
26. Ellner, P. D. & Neu, H. C. (1981). The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. Journal of the American Medical Association 246, 1575-8.
27. Honeybourne, D. & Baldwin, D. R. (1992). The site concentrations of antimicrobial agents in the lung. Journal of Antimicrobial Chemotherapy 30, 249-60.
28. Kinsky, S. C., Avruch, J., Permutt, M. & Rogers, H. B. (1962). The lytic effect of polyene antifungal antibiotics on mammalian erythrocytes. Biochemical and Biophysical Research Communications 9, 503-7.
29. Brajtburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9, 512-31.
30. Anaissie, E., Paetznick, V., Proffitt, R., Adler-Moore, J. & Bodey, G. P. (1991). Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. European Journal of Clinical Microbiology and Infectious Diseases 10, 665-8.
31. Francis, P., Lee, J. W., Hoffman, A., Peter, J., Francesconi, A., Bacher, J. et al. (1994). Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. Journal of Infectious Diseases 169, 356-68.
32. Allende, M. C., Lee, J. W., Francis, P., Garrett, K., Dollenberg, J., Berenguer, J. et al. (1994). Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 38, 518-22.